Slide

Enteris BioPharma rebrands to MOD3 Pharma

Enteris BioPharma, a fully integrated contract development and manufacturing organization, today announced that the company is changing its name to MOD3 Pharma.

A wholly owned subsidiary of SWK Holdings Corp. (SWKH), MOD3 Pharma continues to build on its strong growth agenda by refocusing its service portfolio to supporting investigational drugs in the development of Orally Inhaled and Nasal Drug Products (OINDP).

LEARN MORE

Slide

Your Catalyst to Clinic

MOD3Pharma combines decades of CMC experience with a laser focus on Orally Inhaled and Nasal Drug Products (OINDP) to transform your project into a clinic-ready proposition.

Using a stage-appropriate methodology within the Module 3 framework, our experts work collaboratively with you to manage risk, mitigate delay and reduce cost while ensuring your OINDP product’s quality, safety, and efficacy.

LEARN MORE

Slide

Equipped for Quality Manufacturing

Navigating the supply of your drug product for early phase clinical trials requires a team of scientists with a passion for drug development and the creativity to solve problems decisively. You need a team behind you that have seen it and done it before. Many times before.

At MOD3 Pharma, our seasoned experts start brilliantly with the end in mind, using a stage-appropriate framework to answer every complex element within Module 3. Together, we will transform your project into a clinic-ready proposition.

LEARN MORE

Slide

Enteris BioPharma rebrands to MOD3 Pharma

Enteris BioPharma, a fully integrated contract development and manufacturing organization, today announced that the company is changing its name to MOD3 Pharma.

LEARN MORE

Slide

Your Catalyst to Clinic

MOD3Pharma combines decades of CMC experience with a laser focus on Orally Inhaled and Nasal Drug Products (OINDP) to transform your project into a clinic-ready proposition.

LEARN MORE

Slide

Enteris BioPharma rebrands to MOD3 Pharma

Enteris BioPharma, a fully integrated contract development and manufacturing organization, today announced that the company is changing its name to MOD3 Pharma.

LEARN MORE

Slide

Your Catalyst to Clinic

MOD3Pharma combines decades of CMC experience with a laser focus on Orally Inhaled and Nasal Drug Products (OINDP) to transform your project into a clinic-ready proposition.

LEARN MORE

Risk. Time. Cost. The trifecta of challenges that can keep you awake at night. Because your project matters – it really matters, not just to you, but to the patients that will rely on your therapy to make their lives better.

Navigating the supply of your drug product for early phase clinical trials requires a team of scientists with a passion for drug development and the creativity to solve problems decisively. You need a team behind you that have seen it and done it before. Many times before.

SCHEDULE A MEETING

We really want to talk to you about your next OINDP product.
Let us be your catalyst to clinic.

Ask Us a Question

Our team relish finding answers to questions that haven’t been thought of yet.

Enteris BioPharma rebrands to MOD3 Pharma

Enteris BioPharma, a fully integrated contract development and manufacturing organization, today announced that the company is changing its name to MOD3 Pharma.

Your Catalyst to Clinic

MOD3Pharma combines decades of CMC experience with a laser focus on Orally Inhaled and Nasal Drug Products (OINDP) to transform your project into a clinic-ready proposition.

Finding the Right Formulation

With experience of oral solid, nasal and Injectable dosage forms as well as many OINDPs, MOD3 Pharma brings deep insight and intelligence to formulation science.

Equipped for Quality Manufacturing

Navigating the supply of your drug product for early phase clinical trials requires a team of scientists with a passion for drug development and the creativity to solve problems decisively. You need a team behind you that have seen it and done it before. Many times before.

Enteris BioPharma rebrands to MOD3 Pharma

Enteris BioPharma, a fully integrated contract development and manufacturing organization, today announced that the company is changing its name to MOD3 Pharma.

Your Catalyst to Clinic

MOD3Pharma combines decades of CMC experience with a laser focus on Orally Inhaled and Nasal Drug Products (OINDP) to transform your project into a clinic-ready proposition.

Finding the Right Formulation

With experience of oral solid, nasal and Injectable dosage forms as well as many OINDPs, MOD3 Pharma brings deep insight and intelligence to formulation science.

Equipped for Quality Manufacturing

With specialized equipment for manufacturing liquid and nasal OINDPs, MOD3 Pharma has the technology to turn your formulation into a drug product.

Enteris BioPharma rebrands to MOD3 Pharma

Enteris BioPharma, a fully integrated contract development and manufacturing organization, today announced that the company is changing its name to MOD3 Pharma.

Your Catalyst to Clinic

MOD3Pharma combines decades of CMC experience with a laser focus on Orally Inhaled and Nasal Drug Products (OINDP) to transform your project into a clinic-ready proposition.

Finding the Right Formulation

With experience of oral solid, nasal and Injectable dosage forms as well as many OINDPs, MOD3 Pharma brings deep insight and intelligence to formulation science.

Equipped for Quality Manufacturing

With specialized equipment for manufacturing liquid and nasal OINDPs, MOD3 Pharma has the technology to turn your formulation into a drug product.

Risk. Time. Cost. The trifecta of challenges that can keep you awake at night. Because your project matters – it really matters, not just to you, but to the patients that will rely on your therapy to make their lives better.

Consulting

Product Development

Clinical Supplies

SCHEDULE A MEETING

Ask Us a Question

CONTACT US